Cancer drugs to come under scrutiny

Tuesday, 18 Jul 2017

The Drug Utilisation Sub-Committee of the PBAC has flagged several cancer drugs for review at its next meeting.

The committee says it will look at predicted versus actual use for:

  • Lenalidomide for myelodysplastic syndrome;
  • Paclitaxel, nanoparticle albumin-bound, for metastatic adenocarcinoma of the pancreas;
  • Eculizumab for atypical haemolytic uraemic syndrome (aHUS); and
  • Sunitinib and everolimus for metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET).

Under the remit of an ‘analysis of multiple medicines in a treatment area’ they will also look at ¬†thalidomide, bortezomib, lenalidomide and pomalidomide for multiple myeloma ¬†and bevacizumab, cetuximab and panitumumab for metastatic colorectal cancer.

Already a member?

Login to keep reading.

Email me a login link

© 2023 the limbic